Alphand Veronique, Carrea Giacomo, Wohlgemuth Roland, Furstoss Roland, Woodley John M
Groupe Biocatalyse et Chimie Fine, CNRS, Case 901, Marseille 13288, France.
Trends Biotechnol. 2003 Jul;21(7):318-23. doi: 10.1016/S0167-7799(03)00144-6.
Biocatalysis is coming of age, with an increasing number of reactions being scaled-up and developed. The diversity of reactions is also increasing and oxidation reactions have recently been considered for scale-up to commercial processes. One important chemical conversion, which is difficult to achieve enantio- or enantiotopo- selectively, is the Baeyer-Villiger (BV) oxidation of ketones. Using cyclohexanone monooxygenase to catalyse the reaction produces optically pure esters and lactones with exquisite enantiomeric excess values. Recently, these enzymes and their many applications in synthetic chemistry have been explored. The scale-up of these conversions has been examined with the idea of implementing the first commercial Baeyer-Villiger monooxygenase-based process. Here, we review the state-of-the-art situation for the scale-up and exploitation of these enzymes.
生物催化正逐渐成熟,越来越多的反应得以扩大规模并得到开发。反应的多样性也在增加,氧化反应最近已被考虑扩大规模用于商业生产。一种难以实现对映选择性或对映拓扑选择性的重要化学转化是酮的拜耳 - 维利格(BV)氧化反应。使用环己酮单加氧酶催化该反应可产生具有极高对映体过量值的光学纯酯和内酯。最近,人们对这些酶及其在合成化学中的众多应用进行了探索。已对这些转化反应的扩大规模进行了研究,目的是实施首个基于拜耳 - 维利格单加氧酶的商业流程。在此,我们综述了这些酶扩大规模及应用的最新情况。